Saved in:
| Main Author: | |
|---|---|
| Format: | Recurso digital |
| Language: | |
| Published: |
Zenodo
2026
|
| Online Access: | https://doi.org/10.5281/zenodo.19453042 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1866901184229408768 |
|---|---|
| author | Mishra, Aditya |
| author_facet | Mishra, Aditya |
| contents | <p><span> </span><strong>ABSTRACT</strong></p> <p>*Background:*</p> <p>Refractory Type 2 Diabetes Mellitus (T2DM) requiring high-dose insulin therapy represents a significant clinical challenge. Despite maximum conventional therapy, a subset of patients remains persistently hyperglycemic. Current paradigms favor progressive insulin escalation, yet this often yields diminishing returns and exacerbates weight gain and insulin resistance.</p> <p>*The Hypothesis:*</p> <p>We propose the existence of a distinct clinical subset defined as the <strong>*"High SLC5A2 Expresser Phenotype."* </strong>We hypothesize that in these patients, a vicious cycle is established where exogenous hyperinsulinemia, persistent hyperglycemia, and systemic inflammation act as continuous molecular inducers of the SLC5A2 gene. This results in massive, sustained upregulation of Sodium-Glucose Cotransporter 2 (SGLT2) receptors in the proximal convoluted tubule. Consequently, standard therapeutic doses of SGLT2 inhibitors become pharmacologically inadequate to achieve meaningful glucosuria.</p> <p>*Proposed Intervention:*</p> <p>To rescue this phenotype, we propose a counter-intuitive therapeutic protocol: the gradual cessation of high-dose exogenous insulin (to remove the primary transcriptional inducer of SLC5A2) followed immediately by the administration of *supramaximal doses of SGLT2 inhibitors* under strict structural and functional renal safety criteria (including Corticomedullary Differentiation assessment).</p> <p>*Conclusion:*</p> <p>This hypothesis challenges the standard of care for refractory T2DM, shifting the focus from overcoming insulin resistance with more insulin, to reversing SLC5A2 epigenetic locking. A proprietary clinical scoring system is currently under development to safely identify this specific phenotype for targeted intervention.</p> <p><strong><span>*Keywords:*</span></strong> SLC5A2, SGLT2 Upregulation, Refractory Type 2 Diabetes, Hyperinsulinemia, Supramaximal SGLT2 Inhibition, High SLC5A2 Expresser Phenotype,Refractory Type 2 Diabetes <span> </span>,Insulin cessation <span> </span>,Total SLC5A2 Inducer Burden , Corticomedullary differentiation ,Epigenetic regulation,</p> <p><strong>COPYRIGHT NOTICE AND INTELLECTUAL PROPERTY DECLARATION</strong></p> <p>*© 2026Dr. [Prof Dr Aditya Bikram Mishra ]. All Rights Reserved.*</p> <p>The conceptual framework, theoretical constructs, clinical hypotheses, molecular pathway descriptions, patient phenotype definitions, therapeutic intervention strategies, dietary protocol recommendations, biochemical monitoring frameworks, and all associated original intellectual content presented in this manuscript, including but not limited to the concept of the *"High SLC5A2 Expresser Phenotype (H-SEP)", the *"Total SLC5A2 Inducer Burden"* framework, the *"SLC5A2 Upregulation Vicious Cycle"* model, the *"Supramaximal SGLT2 Inhibitor Dosing Strategy"* in phenotype-selected patients, the **structured insulin dose reduction protocol with biochemical safety monitoring, the **dietary de-induction framework* including specified restrictions of non-vegetarian foods, oily substances, artificial sweeteners, bitter vegetables, and herbal anti-diabetic preparations, and the designation and clinical definition of the *"Very High SLC5A2 Expresser Phenotype (VH-SEP)"* — are the sole and exclusive original intellectual creations of the author, *Prof Dr.Aditya Bikram Mishra , conceived, developed, and documented independently at *[Dibya Aditya Diabetes Care , Cuttack , India ]**.</p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_19453042 |
| institution | Zenodo |
| language | |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | *Understanding the SGLT2 Receptor and its Related Genetics (SLC5A2 Gene): Identifying a Unique Phenotype and Necessary Therapeutic Intervention — A Hypothesis* Mishra, Aditya <p><span> </span><strong>ABSTRACT</strong></p> <p>*Background:*</p> <p>Refractory Type 2 Diabetes Mellitus (T2DM) requiring high-dose insulin therapy represents a significant clinical challenge. Despite maximum conventional therapy, a subset of patients remains persistently hyperglycemic. Current paradigms favor progressive insulin escalation, yet this often yields diminishing returns and exacerbates weight gain and insulin resistance.</p> <p>*The Hypothesis:*</p> <p>We propose the existence of a distinct clinical subset defined as the <strong>*"High SLC5A2 Expresser Phenotype."* </strong>We hypothesize that in these patients, a vicious cycle is established where exogenous hyperinsulinemia, persistent hyperglycemia, and systemic inflammation act as continuous molecular inducers of the SLC5A2 gene. This results in massive, sustained upregulation of Sodium-Glucose Cotransporter 2 (SGLT2) receptors in the proximal convoluted tubule. Consequently, standard therapeutic doses of SGLT2 inhibitors become pharmacologically inadequate to achieve meaningful glucosuria.</p> <p>*Proposed Intervention:*</p> <p>To rescue this phenotype, we propose a counter-intuitive therapeutic protocol: the gradual cessation of high-dose exogenous insulin (to remove the primary transcriptional inducer of SLC5A2) followed immediately by the administration of *supramaximal doses of SGLT2 inhibitors* under strict structural and functional renal safety criteria (including Corticomedullary Differentiation assessment).</p> <p>*Conclusion:*</p> <p>This hypothesis challenges the standard of care for refractory T2DM, shifting the focus from overcoming insulin resistance with more insulin, to reversing SLC5A2 epigenetic locking. A proprietary clinical scoring system is currently under development to safely identify this specific phenotype for targeted intervention.</p> <p><strong><span>*Keywords:*</span></strong> SLC5A2, SGLT2 Upregulation, Refractory Type 2 Diabetes, Hyperinsulinemia, Supramaximal SGLT2 Inhibition, High SLC5A2 Expresser Phenotype,Refractory Type 2 Diabetes <span> </span>,Insulin cessation <span> </span>,Total SLC5A2 Inducer Burden , Corticomedullary differentiation ,Epigenetic regulation,</p> <p><strong>COPYRIGHT NOTICE AND INTELLECTUAL PROPERTY DECLARATION</strong></p> <p>*© 2026Dr. [Prof Dr Aditya Bikram Mishra ]. All Rights Reserved.*</p> <p>The conceptual framework, theoretical constructs, clinical hypotheses, molecular pathway descriptions, patient phenotype definitions, therapeutic intervention strategies, dietary protocol recommendations, biochemical monitoring frameworks, and all associated original intellectual content presented in this manuscript, including but not limited to the concept of the *"High SLC5A2 Expresser Phenotype (H-SEP)", the *"Total SLC5A2 Inducer Burden"* framework, the *"SLC5A2 Upregulation Vicious Cycle"* model, the *"Supramaximal SGLT2 Inhibitor Dosing Strategy"* in phenotype-selected patients, the **structured insulin dose reduction protocol with biochemical safety monitoring, the **dietary de-induction framework* including specified restrictions of non-vegetarian foods, oily substances, artificial sweeteners, bitter vegetables, and herbal anti-diabetic preparations, and the designation and clinical definition of the *"Very High SLC5A2 Expresser Phenotype (VH-SEP)"* — are the sole and exclusive original intellectual creations of the author, *Prof Dr.Aditya Bikram Mishra , conceived, developed, and documented independently at *[Dibya Aditya Diabetes Care , Cuttack , India ]**.</p> |
| title | *Understanding the SGLT2 Receptor and its Related Genetics (SLC5A2 Gene): Identifying a Unique Phenotype and Necessary Therapeutic Intervention — A Hypothesis* |
| url | https://doi.org/10.5281/zenodo.19453042 |